Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 134

1.

Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014.

Distelhorst SR, Cleary JF, Ganz PA, Bese N, Camacho-Rodriguez R, Cardoso F, Ddungu H, Gralow JR, Yip CH, Anderson BO; Breast Health Global Initiative Global Summit on Supportive Care and Quality of Life Consensus Panel Members.

Lancet Oncol. 2015 Mar;16(3):e137-47. doi: 10.1016/S1470-2045(14)70457-7. Review.

PMID:
25752564
2.

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).

Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM.

Support Care Cancer. 2015 Oct;23(10):2917-23. doi: 10.1007/s00520-015-2657-1. Epub 2015 Feb 28.

3.

Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.

Keefe DM, Elting LS, Nguyen HT, Grunberg SM, Aprile G, Bonaventura A, Selva-Nayagam S, Barsevick A, Koczwara B, Sonis ST.

Cancer Chemother Pharmacol. 2014 Oct;74(4):675-80. doi: 10.1007/s00280-014-2526-5. Epub 2014 Jul 25.

PMID:
25055935
4.

Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force.

Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, Herrstedt J, Hopkinson J, Jacquelin-Ravel N, Jatoi A, Kaasa S, Strasser F; ESMO (European School of Medical Oncology).

Ann Oncol. 2014 Aug;25(8):1492-9. doi: 10.1093/annonc/mdu085. Epub 2014 Feb 25. Review.

PMID:
24569913
5.

Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Cardoso F, Bese N, Distelhorst SR, Bevilacqua JL, Ginsburg O, Grunberg SM, Gralla RJ, Steyn A, Pagani O, Partridge AH, Knaul FM, Aapro MS, Andersen BL, Thompson B, Gralow JR, Anderson BO.

Breast. 2013 Oct;22(5):593-605. doi: 10.1016/j.breast.2013.07.050. Epub 2013 Aug 31. Review.

PMID:
24001709
6.

Emerging treatments in chemotherapy-induced nausea and vomiting.

Grunberg SM, Slusher B, Rugo HS.

Clin Adv Hematol Oncol. 2013 Feb;11(2 Suppl 1):1-18; quiz 2 p following 18. Review.

PMID:
23598819
7.

Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics.

Toth MJ, Miller MS, Callahan DM, Sweeny AP, Nunez I, Grunberg SM, Der-Torossian H, Couch ME, Dittus K.

J Appl Physiol (1985). 2013 Apr;114(7):858-68. doi: 10.1152/japplphysiol.01474.2012. Epub 2013 Feb 14.

8.

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.

Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD; Alliance for Clinical Trials in Oncology.

Genes Chromosomes Cancer. 2013 Apr;52(4):385-401. doi: 10.1002/gcc.22036. Epub 2012 Dec 10.

9.

Optimal management of malignant pleural effusions (results of CALGB 30102).

Demmy TL, Gu L, Burkhalter JE, Toloza EM, D'Amico TA, Sutherland S, Wang X, Archer L, Veit LJ, Kohman L; Cancer and Leukemia Group B.

J Natl Compr Canc Netw. 2012 Aug;10(8):975-82.

10.

Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.

Schwartzberg LS, Grunberg SM, Kris MG.

Clin Adv Hematol Oncol. 2011 Nov;9(11 Suppl 27):1-14; quiz 15-6.

PMID:
22362372
11.

Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.

Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D.

J Natl Compr Canc Netw. 2012 Feb;10(2):149-57.

PMID:
22308514
12.

Chemotherapy-induced nausea and vomiting incidence and prevalence.

Grunberg SM.

Am Soc Clin Oncol Educ Book. 2012:541-3. doi: 10.14694/EdBook_AM.2012.32.541.

13.

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ; Cancer and Leukemia Group B.

Cancer. 2012 Sep 1;118(17):4139-47. doi: 10.1002/cncr.26732. Epub 2011 Dec 16.

14.

Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).

Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B.

J Pain Symptom Manage. 2012 Feb;43(2):205-17. doi: 10.1016/j.jpainsymman.2011.09.001. Epub 2011 Nov 21.

15.

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.

Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA; Cancer and Leukemia Group B.

Leukemia. 2011 May;25(5):800-7. doi: 10.1038/leu.2011.9. Epub 2011 Feb 15.

16.

Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients.

Avritscher EB, Shih YC, Sun CC, Gralla RJ, Grunberg SM, Xu Y, Elting LS.

J Support Oncol. 2010 Nov-Dec;8(6):242-51.

PMID:
21265391
17.

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.

Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT.

Support Care Cancer. 2011 Mar;19 Suppl 1:S43-7. doi: 10.1007/s00520-010-1003-x. Epub 2010 Oct 24. Review.

PMID:
20972805
18.

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.

Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; Sancuso Study Group.

Support Care Cancer. 2011 Oct;19(10):1609-17. doi: 10.1007/s00520-010-0990-y. Epub 2010 Sep 12.

19.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group.

Ann Oncol. 2010 May;21 Suppl 5:v232-43. doi: 10.1093/annonc/mdq194. Review. No abstract available.

PMID:
20555089
20.

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.

Einhorn LH, Grunberg SM, Rapoport B, Rittenberg C, Feyer P.

Support Care Cancer. 2011 Mar;19 Suppl 1:S1-4. doi: 10.1007/s00520-010-0920-z. Epub 2010 May 26.

PMID:
20505956

Supplemental Content

Loading ...
Support Center